Mark J. Botti

Sep 7, 2023 | mondaq.com | Mark J. Botti |Jody Boudreault

A Federal Trade Commission (FTC) settlement filed last week with merging pharmaceutical manufacturers re-opens a seemingly foreclosed antitrust path to clearance for parties pursuing non-horizontal mergers and acquisitions where antitrust considerations play a significant role. Amgen announced the ~$28 billion acquisition of Horizon on December 11, 2022, and the parties made their HSR filing on December 29. The FTC issued a "second request" on January 30, 2023.

Aug 31, 2023 | concurrences.com | Baker Botts |Mark J. Botti |Jody Boudreault

A Federal Trade Commission (FTC) settlement filed last week with merging pharmaceutical manufacturers re-opens a seemingly foreclosed antitrust path to clearance for parties pursuing non-horizontal mergers and acquisitions where antitrust considerations play a significant role. Background Amgen announced the $28 billion acquisition of Horizon on December 11, 2022, and the parties made their HSR filing on December 29. The FTC issued a “second request” on January 30, 2023.